EUCTR2012-000562-37-HU进行中（未招募）不适用
A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All subjects:
- •Male and female Caucasian subjects 18 to 70 years of age
- •At least 50 kg and body mass index (BMI) within 18-35 kg/m2.
- •CYP2C9 wild-type (CYP2C9*1 homozygous carriers)
- •Hepatic impairment:
- •Subjects must have either mild, moderate or sever hepatic impairment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 32
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 16
排除标准
- •All subjects
- •Hepatic impairment due to non-liver disease.
- •Use of other investigational drugs within certain timelines
- •Donation or loss of 400 mL or more of blood or plasma within eight (8) weeks prior to initial dosing
- •History of cardiac rhythm abnormalities or cardiac rhythm abnormalities identified in the 24-h Holter ECG recording including episodes of bradycardia (HR < 50 bpm) during waking hours and/or arrhythmic episodes; subjects with history or presence of ventricular rhythm disturbances (ventricular extra-systoles >100/24h, or higher grade), or supraventricular arrhythmias (other than occasional supraventricular ectopic beats with a maximum of 5 subsequent ectopic beats per event) or subjects with conduction disturbances (higher than AV-block grade 1) or bradycardia or tachycardia.
- •History of cardiac catheter ablation.
- •Women of child-bearing potential
- •History of malignancy of any organ system
- •Recent and/or recurrent history of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease)
- •History or presence of symptomatic postural hypotension or syncope.
- •Total WBC or lymphocyte counts which falls outside the 1.5-fold local laboratory normal range or platelet count < 30,000/µL at screening or baseline.
- •Clinically significant infection or recent vaccination with live-attenuated vaccines.
- •History or presence of hepatitis B or C and/or positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result at screening.
- •History or presence of coronary heart disease (stable or unstable), myocardial infarction, myocarditis, cardiomyopathy, heart failure NYHA II - IV.
- •Hepatic impairment:
- •History or presence of any non-controlled and clinically significant disease that could affect the study outcome or that would place the patient at undue risk.
- •Any surgical or medical condition other than hepatic impairment which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the study subject in case of participation in the study.
- •Treatment with certain drugs
- •Healthy subjects:
- •History or presence of any clinically significant disease of any major system organ class including (but not limited to) cardiovascular, metabolic, renal, neurological or psychiatric diseases.
- •Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study.
研究者
相似试验
进行中（未招募）
1 期
A Single-Dose, Open-Label, Parallel Group Study to Characterize the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of Reslizumab Following Subcutaneous Administration in Children with Asthma (6 to Less Than 12 Years of Age)AsthmaEUCTR2017-002060-40-Outside-EU/EEATeva Branded Pharmaceutical Products R&D, Inc.36
进行中（未招募）
不适用
A study to assess the pharmacokinetics of LCZ696 in subjects with hepatic impairment compared to matched healthy subjectsMild and moderate hepatic impairmentMedDRA version: 14.1Level: PTClassification code 10024670Term: Liver disorderSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2012-000983-27-DEovartis Pharma Services AG32
招募中
1 期
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964)Healthy Adult ParticipantsCTIS2022-502952-30-00Janssen - Cilag International32
进行中（未招募）
1 期
An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic functioActivated Phosphoinositide 3-Kinase Delta SyndromeMedDRA version: 20.0Level: PTClassification code: 10078281Term: Activated PI3 kinase delta syndrome Class: 100000004850CTIS2023-508519-22-00Pharming Technologies B.V.32
已完成
不适用
An open-label, parallel-group, single-dose study to evaluate the absolute bioavailability and tolerability of subcutaneous UCB4940 in healthy subjectsrheumatoid arthritisNL-OMON41792CB Celltech30